Cargando…
Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors
Heart failure with preserved ejection fraction (HFpEF) is a condition with increasing disease burden. Prevalence of HFpEF is increasing, reflecting an increasingly elderly and comorbid population, as well as reinforcing the need for more treatments for this disease. The pathophysiology of HFpEF is c...
Autores principales: | Heath, Rebecca, Johnsen, Håkon, Strain, W. David, Evans, Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873330/ https://www.ncbi.nlm.nih.gov/pubmed/35084695 http://dx.doi.org/10.1007/s13300-022-01204-4 |
Ejemplares similares
-
Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction
por: Clemmer, John S., et al.
Publicado: (2023) -
Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction
por: De Lorenzi, Andrea Beatriz, et al.
Publicado: (2023) -
EMPEROR-Preserved: SGLT2 inhibitors breakthrough in the management of heart failure with preserved ejection fraction
por: Wagdy, Kerolos, et al.
Publicado: (2021) -
Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
por: Pabel, Steffen, et al.
Publicado: (2021) -
SGLT2 inhibitors in heart failure with reduced ejection fraction
por: Das, Uday Sankar, et al.
Publicado: (2021)